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Trends
Millions of animals are used for the
routine production of antibodies for
research, monitoring, diagnostics,
and therapeutics, although the true
magnitude of use is unknown.
The EU Directive on the protection of
animals used for scientiﬁc purposes
(2010/63/EU) requires that animals
are not be used for scientiﬁc purposes
where a non-animal alternative exists.
Animal-friendly afﬁnity reagents (AFAs)
from non-immunised sources and
produced by phage display are mature
and available to replace animal immu-
nisation methods for antibody
production.
In line with Directive 2010/63/EU, an
EU-wide replacement programme
must now take precedence. In this Opi-
nion article, we outline recommended
actions that must be prioritised.
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The multibillion-dollar global antibody industry produces an indispensable
resource but that is generated using millions of animals. Despite the irrefutable
maturation and availability of animal-friendly afﬁnity reagents (AFAs) employing
na€ive B lymphocyte or synthetic recombinant technologies expressed by
phage display, animal immunisation is still authorised for antibody production.
Remarkably, replacement opportunities have been overlooked, despite the
enormous potential reduction in animal use. Directive 2010/63/EU requires that
animals are not used where alternatives exist. To ensure its implementation, we
have engaged in discussions with the EU Reference Laboratory for alternatives
to animal testing (EURL ECVAM) and the Directorate General for Environment
to carve out an EU-led replacement strategy. Measures must be imposed to
avoid outsourcing, regulate commercial production, and ensure that antibody
producers are fully supported.
The Hidden Use of Animals in Consumer Society
A young woman visiting her local supermarket to do her weekly shopping knows that, in
this conscientious-consumer-driven society, she will be overwhelmed with choices that
allow her to make informed decisions about her own environmental footprint, maintain a
healthy lifestyle, and patronise non-exploitative industries. The information that helps her do
so is clearly visible on the packaging of the shampoo especially formulated for sensitive skin
and the nutrient-supplemented, low-sugar, fair-trade cereal that she chooses as she
browses the aisles. However, on this occasion the main reason for her visit is to pick up
a pregnancy test that will help her plan her future. She knows that the three items she has
just selected will all contribute to protecting her family and the environment they live in,
but does she know that, despite the reassuring information on the packaging, she has just
picked up three items that still use animals? How is that possible? The shampoo conforms
to EU cosmetics regulation 1223/2009 by not being tested on animals, the cereal is animal-
product free, and the pregnancy test is a simple over-the-counter diagnostic test designed
for home use.
What the information on the packaging does not tell her about is the hidden use of animals in an
afﬂuent, US$80-billion industry that creates millions of animal-derived monoclonal and poly-
clonal antibodies (see Glossary) to detect a vast range of molecules indicative of state of
health, safety, or the environment. Antibodies are used, for example, as an indispensable link in
the health-care chain, contributing to enhanced patient care and reduced public health costs.
Antibody-based tests are used to diagnose and monitor infectious or chronic diseases, to
manage oncology treatment, or, in rapid-test format, often available over the counter, to monitor960 Trends in Biotechnology, December 2016, Vol. 34, No. 12 http://dx.doi.org/10.1016/j.tibtech.2016.05.017
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Glossary
Afﬁnity reagents: antibodies,
peptides, nucleic acids, and other
small molecules that bind speciﬁcally
to a molecule of interest to detect,
capture, or modify its mode of action.
Animal-friendly afﬁnity reagents
(AFAs): binders that are not derived
from animal immunisation and do not
require the use of animals at any
stage of production.
Ascites method: hybridoma cells
are injected into the peritoneal cavity
surrounding the gut, initiating the
development of tumours and the
secretion of an antibody-rich ﬂuid
called ascites ﬂuid.
B lymphocytes: cells of the adaptive
immune system that bind to a foreign
body or antigen and secrete highly
speciﬁc antibodies to destroy or block
activity. Adaptive immunity creates
immunological memory after an initial
encounter and leads to an enhanced
response to subsequent encounters.
Combinatorial diversiﬁcation [V(D)
J] recombination: the unique
mechanism of genetic recombination
that occurs only in developing
lymphocytes during the early stages
of T and B lymphocyte maturation.
Hybridoma: B lymphocyte cells that
bind speciﬁcally to the antigen are
harvested from the spleen of
immunised animals. These isolated B
lymphocytes are then fused with
immortal B cell cancer cells.
Human antimouse antibody
(HAMA): immune response to mouse
antibodies.
Monoclonal antibodies: secreted
by one B cell lineage or clone. These
identical, monospeciﬁc antibodies are
secreted from the selected hybridoma
cell.
Panning: an afﬁnity selection
technique that selects peptides or
proteins binding to a speciﬁc target.
Phage display: a gene encoding a
protein of interest (in this case, an
antibody fragment) is ligated to the
gene encoding either the minor or
major coat protein of the (bacterio)
phage, causing it to be ‘displayed’ on
the outside, fused to the coat protein,
where it is accessible for subsequent
selection procedures, while retaining
the gene for the protein on the inside.
Polyclonal antibodies: secreted by
different B cell lineages. For research
purposes, these antibodies are
collected from the serum of
immunised animals.fertility, ovulation and pregnancy, sexually transmitted diseases, substances of abuse, and
performance-enhancing drugs.
Also, as a vital tool to safeguard the environment and consumer industry, antibodies may be
used to detect or extract the alarming number of potential chemical contaminants, allergens,
microbiologicals, natural toxins, food constituents, pharmaceutical and veterinary drugs, hor-
mones, metals, agricultural contaminants, and pesticides that can exist in our food, beverages,
and water. They can predict the safe limit for a potentially harmful ingredient in a cosmetic or
household product or control the quality of biological agents such as vaccines or botulinum
toxin.
The tests that are employed in these examples appear to be far removed from animal experi-
mentation since no animals were directly tested on. However, the molecule to be detected is
repeatedly injected into the animal, initiating a hyperimmune response. Months later, antibodies
are extracted and incorporated into an in vitro, animal-free test for the detection of the molecule.
So in reality we are not replacing animals but simply substituting methods in which the animal use
is direct for other methods where the animal use is buried several layers deep in the production
process, and our ultimate aim, to replace needless animal use, is not achieved.
Lack of Clarity about the Impact of Antibody Production on Animal Welfare
Also overlooked are the sheer numbers of animals that are sacriﬁced to produce antibodies and
the associated and unaccounted-for animal-welfare issues [1,2].
Measures to improve animal-welfare standards by reducing or reﬁning animal-derived antibody
production methods were initiated in 1998 following the publication of a statement by the
European Centre for the Validation of Alternative Methods (ECVAM) scientiﬁc advisory commit-
tee. This statement recommended that, following the immunisation protocol, the propagation of
monoclonal antibodies in the ascites of the abdominal cavity was no longer scientiﬁcally
necessary. Accordingly, competent authorities in European Member States responsible for
the implementation of EU legislation regarding the welfare of animals used for scientiﬁc purposes
should now no longer authorise project license applications proposing antibody propagation by
the ascites method. Recommendations for reﬁning methods for producing polyclonal anti-
bodies were also published.
Remarkably, workshop reports that were distributed to all EU Member State competent
authorities highlighted advances in novel recombinant DNA-based technologies and direct
cloning into plasmids. These reports envisaged that, ‘in the near future’, phage display, an
advanced technology capable of producing binders ‘without prior immunisation of B cell donors
(would) avoid the need to use living animals’ [3–5]. So looking back, this discrepancy with reality
is not easy to understand. Eighteen years later, immunised animals are still heavily relied on
for hybridoma (monoclonal–with subsequent ampliﬁcation in vitro), polyclonal, and even
some recombinant antibody production methods. There are 123 EU companies offering
714 000 catalogue antibodies produced either in-house or through international collaborations
(more than 2.5 billion worldwide). Furthermore, undetermined numbers of antibodies are
generated through custom-made production by companies and research institutes. Demand
is set to increase because the number of antibodies that could be generated in the future,
including variants, in all different immunoassays, appears to be limitless. The human genome
has 20 000–25 000 protein-encoding genes. Due to alternative mRNA splicing and post-
translational modiﬁcations, the number of proteins and the potential for the generation of
antibodies exceed this number tenfold. It is not uncommon to see hundreds of antibodies
generated for the same target (e.g., more than 900 for P53 [6,7]). Larger numbers of animals
are required to increase the chances of success if the desired antibody is expected to distinguishTrends in Biotechnology, December 2016, Vol. 34, No. 12 961
Procedure: ‘any use, invasive or
non-invasive, of an animal for
experimental or other scientiﬁc
purposes, with known or unknown
outcome, or educational purposes,
which may cause the animal a level
of pain, suffering, distress or lasting
harm equivalent to, or higher than,
that caused by the introduction of a
needle in accordance with good
veterinary practice’.
Recombinant antibodies:
generated in vitro using synthetic
gene manipulation techniques.
Replacement, reduction, and
reﬁnement (3Rs): replacement–
alternative methods that avoid or
replace the use of animals;
reduction–experimental design
approaches that minimise the
number of animals used per
experiment; reﬁnement–focusses on
the breeding, accommodation, care,
and use of animals in procedures
and minimising any pain, suffering,
distress, or lasting harm.
Somatic hypermutation: a
mechanism that diversiﬁes B
lymphocyte receptors used to
recognise foreign elements (antigens)
during afﬁnity maturation and allows
the immune system to adapt its
response to new threats.closely related isoforms within or across species or other subtle changes (e.g., phosphorylated
versus non-phosphorylated targets).
Yet the actual number of animals used to generate these antibodies is not known. According
to the latest EU statistics on the number of animals used for scientiﬁc purposes [8], animal
procedures (see Glossary) for antibody production are immersed into 3 different categories,
that includes all animal procedures for ‘production and quality control of products and devices
for human/veterinary medicine and dentistry’ (categories 2.4 and 2.5) and ‘other’ (category
2.9). While the combined total number of animals used in these three categories is 2.7 million,
or 23.18% of total animal use, it is not possible to determine what proportion of this animal use
is attributed to the production of antibodies alone. Only two of the EU Member State countries
publish this information in their own national statistics. In 2013, the UK reported the use of
9522 animals to produce antibodies (1433 monoclonal and 8089 polyclonal) [9]–0.25% of the
combined total use of animals in categories 2.4, 2.5, and 2.9 (triple the number used in
European-wide cosmetics testing, before a ban on animal use was imposed). In the same
year, The Netherlands used more than double the number of animals to produce antibodies,
with 25 697 animals [10] or 34% of the combined total use of animals in these three
categories. These statistics give no insight into the full impact on animals because antibodies
are also outsourced internationally, in countries where animal welfare is less well regulated,
and imported into the EU.
Protecting the Welfare of Animals Used for Scientiﬁc Purposes, Including
Antibody Production, as Deﬁned by Directive 2010/63/EU
Directive 2010/63/EU legislates on the protection of animals used for scientiﬁc purposes,
supporting replacement, reduction, and reﬁnement (the 3Rs) in strict hierarchy [11].
The 3Rs are the guiding principles underpinning the humane use of animals in scientiﬁc research
and are embedded in national and international legislation regulating the use of animals in
scientiﬁc procedures. The Directive seeks to facilitate and promote the advancement of non-
animal alternative approaches; namely, techniques that could provide the same or higher levels
of information as obtained from animal procedures. Regarding the 3Rs principle of replacement
(article 4) and choice of method (article 13), the Directive asserts that ‘wherever possible, a
scientiﬁcally satisfactory method or testing strategy, not entailing the use of live animals, shall be
used instead of a procedure’ and that an animal procedure should not be ‘carried out if another
method or testing strategy for obtaining the result sought, not entailing the use of a live animal, is
recognised under the legislation of the Union’. It requires that competent authorities, appointed
in each Member State, evaluate and authorise projects, including generic projects, when
conducted using established methods for testing, diagnostics, or production, such as the
large-scale commercial production of antibodies. The Directive also stipulates that ‘The Com-
mission should also conduct periodic thematic reviews concerning the replacement, reduction
and reﬁnement of the use of animals in procedures’.
Launched as part of the Commission's commitment to alternative approaches to the use of
animals, the duties of the EURL ECVAM are deﬁned in annex VII of the Directive and include
‘coordinating and promoting the development and use of alternatives to procedures including
in the areas of basic and applied research and regulatory testing; coordinating the validation
of alternative approaches at Union level; acting as a focal point for the exchange of information
on the development of alternative approaches; setting up, maintaining and managing public
databases and information systems on alternative approaches and their state of development;
and promoting dialogue between legislators, regulators, and all relevant stakeholders, in
particular, industry, biomedical scientists, consumer organisations and animal-welfare groups,
with a view to the development, validation, regulatory acceptance, international recognition, and
application of alternative approaches’.962 Trends in Biotechnology, December 2016, Vol. 34, No. 12
Finding the Needle in the Haystack in vitro by Adopting the Same in vivo
Mechanism
Technology has evolved over the past 20 years and antibody production by animal-friendly
methods has grown to a level of scientiﬁc sophistication that outweighs obsolescent animal
immunisation protocols.
Increasing numbers of different animal friendly afﬁnity reagents (AFAs) have been developed or
are commercialised. They are generated independently of any living immune system and are
available to replace animal immunisation techniques for a wide range of applications. AFAs are
selected in vitro by phage, ribosome, or yeast display. These are typically antibodies, but also
include non-antibody afﬁnity reagents such as DARPins, afﬁbodies, monobodies, anticalins,
and others [6,12]. In this Opinion article, we particularly focus on recombinant antibodies
produced by phage display because they are the most technologically mature and compatible
with the usual scientiﬁc applications.
Rather than being manufactured to ‘look’ or ‘act’ like antibodies, antibodies produced by phage
display are the genuine article, adopting the same biological mechanisms that are employed by
the in vivo adaptive immune system and that are also commercially exploited to produce animal-
derived antibodies (Figure 1). The resulting phage display antibodies are thus developmentally,
functionally, and structurally indistinguishable from those produced in vivo. This supports the
requirement within Directive 2010/63/EU for a non-animal alternative to provide the same or
higher level of information as the animal procedure, justifying its replacement.
A New Mindset for Project Application, Evaluation, and Authorisation
Misconceptions regarding practical measures such as cost, intellectual property stipulations,
implementation, relevance, scientiﬁc applicability, and being limited to pharmaceutical applica-
tions obviously still broadly exist, along with the assumption that these misconceptions apply to
all antibodies and other AFAs produced by phage display rather than being rare and exceptional
cases. Consequently, project applications for antibody production in animals, from smaller
academic to large-scale (5-year duration) commercial projects, are still authorised by Member
State competent authorities. These misconceptions are addressed in Table 1.
This notion should now be overturned and project applications should be authorised only in rare
and exceptional cases of single antibody production, to be determined only on a case-by-case
basis. Practical competence may be acquired by gaining access to the abundance of pub-
lications, including full methodology breakdowns, that exists to assist researchers and technical
staff wishing to establish the new technology in their facility. In the hands of competent
personnel, the design of a good phage display library and routine panning and selection
rounds will be adequate to produce antibodies of afﬁnity at least equivalent to those produced
using immunised animals for the vast majority of antigens. Otherwise, there are many in vitro
techniques available to improve antibody binding afﬁnity, speciﬁcity, and other characteristics
in cases where routine panning and selection does not produce the desired result and further
intervention is required, without resorting to animals. Acquisition of genetic material from the
B lymphocytes of immunised donors (human or animal depending on the intended target)
enriches the antibody population for certain antigens. However, this produces a non-renewable
library unsuitable for the selection of multiple antibodies to unrelated targets and should be
proposed only in exceptional cases where in vitro afﬁnity maturation techniques have not
produced a suitable candidate.
Interestingly, several large-scale comparisons have been completed or are ongoing in academic
programmes aiming to generate binders to many antigens; for example, the Structural Geno-
mics Consortium SH2 Pilot, the EU programme Afﬁnity Proteome and AFFINOMICS, and theTrends in Biotechnology, December 2016, Vol. 34, No. 12 963
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Figure 1. Schematic Showing How the Biological Mechanisms Employed by the in vivo Adaptive Immune System Are Adopted to Produce Phage
Display or Animal-Derived Antibodies. Same-colour boxes highlight areas of similarity [7,12,18–26]. Colour-matched boxes depict similar processing stages in (A)
and (B). The three immunoglobulin loci (IgG heavy and light kappa and lambda chains) contain multiple copies of three V(D)J gene segments encoding the variable
(binding) regions of the antibody (pink). In a process called combinatorial diversiﬁcation, evolved by nature and unique to antibody genes, one copy of each type of
gene segment is randomly recombined in any given lymphocyte (green). This allows a small number of genes to produce huge molecular diversity (roughly 3  1011
combinations) at the antibody-binding site [18]. This combinatorial mechanism is exploited in antibody production. Whereas animal immunisation and myeloma cell fusion
are required to produce an antibody-expressing immortal hybridoma for each new target, the recombined antibody-encoding gene segments from human B
lymphocytes can simply be copied and transferred into a non-immunised phage display library [12,19] to achieve vast molecular diversity in vitro (blue). In a highly
efﬁcient selection process analogous to ﬁnding a needle in a haystack and resembling that which takes place in nature, a phage antibody is selected during consecutive
‘panning’ rounds (purple) and expanded (dark blue) [7,19,20]. During the course of a host's immune response, somatic hypermutation in the variable, antigen-binding
coding sequences followed by competitive clonal selection ensures that the antibody afﬁnity continues to improve. Similar afﬁnity maturation based improvements are
easily adopted post selection, if required, because the gene encoding the antibody is accessible inside the phage. This generates diversity beyond that achievable by the
natural immune response, in consequence of accessibility to a much larger combinatorial space and facilitating raising antibodies against basically any structure (light
blue) [21–25].large, ongoing NIH Common Fund Protein Capture Initiatives. All of these large programmes
explicitly support animal-free binder generation methods and the results clearly demonstrate
that phage display-derived afﬁnity reagents of various types not only are equivalent to hybridoma
antibodies, but have bypassed hybridoma technology [12,13].
These programmes broadly demonstrate that this method has been standardised to an extent
that yields consistently high-quality products and facilitates ease of understanding of the
technology and the adoption of the method by the wider scientiﬁc community. In addition,
there are many other academic and commercial groups that have published step-by-step964 Trends in Biotechnology, December 2016, Vol. 34, No. 12
Table 1. A Comparative Overview of the Technical Considerations in Phage Display and Animal
Immunisation-Derived Antibody Productionb
Technical Factor Recombinant Anti-
body Expression
From Naïve Phage
Display Libraries
Monoclonal Antibody
Production
Polyclonal Antibody
Production
Refs
Reliance on Animals None. Not reliant on in
vivo immune response.
One-off development of
library, renewable
resource, equivalent to
lifetime supply of
animals.
Derived from animal
immunisation: new
animals required for
each new target.
Derived from animal
immunisation; new
animals required for
each new target, higher
volumes, new batches.
[7,12,
25–27]
Facilities Required Cell (mammalian and
bacterial) culture
facilities, standard
equipment for molecular
biology and protein
analysis.
Animal housing facilities upkeep, immunisation and
animal care, cell (mammalian) culture facilities,
standard equipment for protein analysis.
[12]
Time Required Six months or less for
one-off development of
library. Weeks for
selection and clonal
expansion of antibody
candidates, from
existing libraries.
Typically 6–8 months
(protein antigen) or 12–
15 months (smaller, less
immunogenic
molecules) for
development of immune
response, fusion, and
characterisation.
Typically 2–4 months for
development of immune
response, harvest, and
puriﬁcation.
a
Reliability of Candidate
Selection
High. Acquisition of rare
speciﬁcities to targets
away from the inﬂuence
of the natural immune
response (e.g., against
conserved epitopes,
toxins, pathogens, non-
immunogenics, closely
related epitopes, cross-
reactivities).
Varied. Natural immunity may limit response to
certain targets including toxins, pathogens, non-
immunogenic molecules, and closely related
epitopes. May require conjugation to carrier protein
and careful identiﬁcation strategy. Antibodies
vulnerable to negative selection.
[12,25,27]
Antibody Speciﬁcity Excellent. Achieved by
exposure of antibody
candidates to multiple
solution targets of
interest for reduced
cross-reactivity or DNA
directly and readily
accessible for post-
selection afﬁnity
maturation-based
techniques.
Varied. Dependent on
immunisation response
and efﬁciency of clonal
selection procedure.
Varied. Dependent on
immunisation response.
[12,17,
25,27,28]
Afﬁnity nM to mM: optimised by
design of biological
milieu and can be
improved to pM or fM
level by afﬁnity
maturation-based
techniques.
nM to mM: limited by
immune response and
afﬁnity ceiling effect of
the B cell response.
Undeﬁned: due to
multiple epitope
recognition and limited
by immune response.
[12,25,27]
Validation Issues Easy access to
sequencing data for
high-level scientiﬁc
validation. Immortal
expression of antibody
to target of interest
Sequencing data rarely
acquired. Hybridoma
produces indeﬁnite
supply of selected
antibody but random
mutation/genetic drift
Nonspeciﬁc binders and
batch-to-batch variation
(even in the same
animal) meaning that
they may not recognise
the same target and
[7,17,
29,30]
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Table 1. (continued)
Technical Factor Recombinant Anti-
body Expression
From Naïve Phage
Display Libraries
Monoclonal Antibody
Production
Polyclonal Antibody
Production
Refs
achievable by
expression in cell line.
Resulting excellent lot-
to-lot consistency
means revalidation not
required.
can occur. May exhibit
poor binding
characteristics or
speciﬁcity.
each batch must be
revalidated. May exhibit
poor binding
characteristics or
speciﬁcity.
Formats ScFv or Fab fragment
compatible with
bacterial expression
systems. Post-selection
engineering produces
various formats
including whole-
antibody monoclonal
isotypes (IgG, IgA, IgE),
ScFv-Fc, and polyclonal
compatible with all
standard laboratory
applications.
Various formats
available reliant on the
output generated by the
immune response and
success of the
puriﬁcation process.
No control over format. [7,12,31]
Quantity of Antigen
Required
1–100 mg (selection by
ELISA).
Typically 4 mg for ﬁve
mice (immunisation and
selection by ELISA).
Typically 1–2.5 mg for
two rabbits or 4 mg per
goat (immunisation and
selection by ELISA)
[12]a
Antibody Generation
Pipeline
Amenable to
automation and high
throughput, multiple
target selection, and
miniaturisation.
High throughput
possible for selection of
candidates only after
lengthy immunisation
process.
Not amenable to high
throughput.
[7,12,
25,27]
Therapeutic
Applications
100% humanisation
since derived from
human B lymphocytes
or synthetic.
Immunogenicity lower,
making these more
likely candidates for
therapeutic
applications.
Up to 95%
humanisation possible.
High immunogenicity
against therapeutic
candidates [human
antimouse antibody
(HAMA)] requiring
resolution by
humanisation or
deimmunisation
strategies.
Not applicable. [12,26,28]
Expertise Requires knowledge of
molecular biology
techniques (PCR,
cloning, vector design,
sequencing,
immunodetection) and
competence in a range
of mammalian/bacterial
cell culture techniques.
Requires competence/training in animal care and
handling, extensive knowledge of immunisation
strategies and immunodetection, and competence
in a range of cell culture techniques.
[12]
ahttp://www.thermoﬁsher.com/uk/en/home/life-science/antibodies/custom-antibodies/custom-antibody-production.html
bAbbreviations: ScFv, single-chain fragment variable; Fab, - fragment antigen- binding; Fc, fragment crystallisable.methodologies, available at online bookstores and libraries (for example, [7,14–16]). Commercial
entities like AbD, and Yumab and the Recombinant Antibody Network universities consortium
have picked up the technology to make animal-free antibodies commercially available to
everybody. Therefore, individuals not wanting to produce antibodies themselves can rest966 Trends in Biotechnology, December 2016, Vol. 34, No. 12
assured that phage display-produced antibodies and custom services are commercially
available, intended for use in the pharmaceutical, in vitro diagnostics (IVD), and life science
sectors.
Call for the Replacement of Animal Immunisation Techniques
The existence of AFAs has reduced the reliance on animal use to a very minor extent. However,
these mature methods currently coexist alongside animal-derived antibody production techni-
ques and the technology remains unadopted by the wider scientiﬁc community. It is thus time to
break down the barriers built on foundations of misconception. In light of the emergence and
maturation of AFAs and the implementation of the 3Rs through a strict hierarchy imposed by
Directive 2010/63/EU, it is indisputable that an EU-wide replacement programme must now take
precedence.
To facilitate this replacement, in recognition of the EURL ECVAM's responsibilities as outlined in
Directive 2010/63/EU to promote the scientiﬁc and regulatory acceptance of alternative meth-
ods that are of importance to basic and applied research and regulatory testing, we have
engaged in discussions with the EURL ECVAM and Directorate General for Environment with a
view to carving out a strategy for the replacement of animal-derived antibody production
methods. We have focussed on the phage display antibody production methodology as a
scientiﬁcally applicable and practically available alternative that provides a replacement method
as accessible as the validated and accepted alternative methods featuring in Organisation for
Economic Co-operation and Development (OECD) regulatory testing guidelines. However, in
order that the full range of options can be reviewed, we encourage other AFA competent experts
to engage with us.
We recommend that the following actions are prioritised.
(i) The replacement of animal immunisation methods for antibody production (including the
generation of polyclonal antibodies in animal serum, the production of hybridomas from
animal spleen cells fused to myeloma cells, and the subsequent ampliﬁcation of monoclonal
antibodies by the ascites or tissue culture supernatant method, and the use of hyper-
immunised animals for the production of recombinant antibodies) within EU Member States
or through international cooperation, including the import of antibodies and antibody-con-
taining products, unless it can be demonstrated on a case-by-case basis that AFAs cannot
be applied.
(ii) An expert working group should be established to set up a roadmap for moving away from
animal immunisation-based techniques for antibody production, in light of the scientiﬁc
feasibility and commercial availability of AFAs.
(iii) Implementation programmes should be set up to facilitate the transfer of establishments to
the new technology. These should include centres of excellence for training in AFA-based
technologies to ensure that antibody producers are fully supported.
(iv) Measures should be taken to ensure that animal-derived antibodies manufactured outside
the EU adhere to European standards to avoid ethics dumping in regions where animal
welfare is less well regulated.
(v) The EURL ECVAM should extend its ﬁeld of activities with its international collaborative
partners to include the production of AFAs and their subsequent use.
(vi) EU and national agencies who are committed to the 3Rs and who execute EU regulations at
an operational level for the commercial production of cosmetics, medicines, household
products, and food or to safeguard our health or the environment should reinforce this action
and no longer permit the import or use of animal-derived antibodies and antibody-containing
products aimed to monitor, detect, diagnose, or extract targets of interest.Trends in Biotechnology, December 2016, Vol. 34, No. 12 967
Outstanding Questions
Not including socioeconomic reasons
such as time constraints, cost, conve-
nience, or lack of expertise, in the
hands of competent experts what
exceptional circumstances might lead
to project authorisation for animal-
derived antibody production against a
target antigen?
What barriers exist to the adoption of
recombinant methods of antibody
development/production and use by
research institutes, industry, and end
users? How can these barriers be
overcome?
What role could be played by regula-
tory authorities, ethics committees,
publishers, industry, funders, and end
users to encourage the routine produc-
tion and commercialisation of AFAs or
to restrict animal-derived antibody pro-
duction, including their import?
What are the advantages of recombi-
nant antibody production methods
over monoclonal and polyclonal anti-
body production methods?
How can phage display antibody pro-
duction be adapted to produce the
characteristic desired in a polyclonal–
namely, multiple epitope recognition?
What advantage can AFA polyclonals(vii) Subsequent reports from the Commission to the Council and the European Parliament on
the statistics on the number of animals used for experimental and other scientiﬁc purposes
should include data on the use of animals for antibody production as an independent
category.
Concluding Remarks
Antibody production by phage display adopts the same mechanistic principles as those
employed by the in vivo adaptive immune system and exploited for scientiﬁc research and
commercial purposes. Consequently, the antibodies produced by these methods are function-
ally indistinguishable to the extent that recombinant antibodies provide the ‘same or higher level
of information as the animal procedure’, as stipulated by Directive 2010/63/EU.
Despite the emergence of better-quality in vitro technologies (see Outstanding Questions) to
tackle a problem that continues to be overlooked [17], obsolete animal-based antibody pro-
duction methods persist. We have at our disposal a mature and widely used technology that is
set to have an enormous impact on animal use owing to the fact that the reliance on antibodies
by biomedical scientists, health-care professionals, and consumers impacts all areas of
research, development, and safety testing. For that reason, it is bewildering to consider that,
despite the readiness of new molecular methodologies and the wealth of literature to support
implementation, and despite the growing availability of companies offering AFAs, antibodies are
continuing to be produced using animal immunisation techniques. It is even more perplexing that
we are not already deeply committed to a programme of replacement of animal-derived antibody
production techniques. To encourage technical discussions that will address any arising issues
and feed into an EU-led replacement programme, to ensure that a consolidated expert opinion is
reached and that a level playing ﬁeld exists for all antibody producers, we have made available a
Linkedin.com group forum: AFAs–Animal Friendly Afﬁnity-reagents. To stimulate discussion,
please see Outstanding Questions.
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